Financials in USD. Standardized financial statements.
A compact view of how Parnell Pharmaceuticals Holdings Ltd turns revenue into operating income and net income.
| Metric | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $34.17M | $30.00M | $28.99M | $26.55M | $19.13M | $19.97M | $19.89M | $9.79M | $11.74M | $12.61M |
| Revenue Growth? | +13.9% | +3.5% | +9.2% | +38.8% | -4.2% | +0.4% | +103.2% | -16.6% | -6.9% | 0.0% |
| Cost of Revenue? | $14.90M | $12.48M | $11.60M | $11.02M | $9.75M | $8.98M | $7.75M | $6.42M | $5.64M | $4.32M |
| Gross Profit? | $19.26M | $17.52M | $17.39M | $15.52M | $9.38M | $10.99M | $12.15M | $3.37M | $6.10M | $8.29M |
| Gross Margin? | +56.4% | +58.4% | +60.0% | +58.5% | +49.0% | +55.0% | +61.1% | +34.5% | +52.0% | +65.7% |
| Operating Expenses? | $17.92M | $20.84M | $16.95M | $12.10M | $19.77M | $28.85M | $24.60M | $9.08M | $5.38M | $4.85M |
| Operating Income? | $1.35M | $3.78M | $1.36M | $2.61M | -$14.27M | -$17.86M | -$12.45M | -$7.09M | $715,955 | $3.43M |
| EBITDA? | $6.00M | $4.23M | $2.40M | $5.26M | -$5.91M | -$15.24M | -$10.97M | -$5.84M | $2.46M | $4.73M |
| Income Before Tax | -$1.42M | -$15.05M | -$6.95M | $337,039 | -$23.12M | -$21.68M | -$13.74M | -$14.35M | -$4.15M | $669,857 |
| Income Tax Expense | $684 | $14,989 | $232,817 | $207,419 | $12,111 | $9,054 | $2,113 | $2.98M | -$672,989 | $602,513 |
| Net Income? | -$1.42M | -$15.06M | -$7.18M | $129,620 | -$23.13M | -$21.69M | -$13.74M | -$17.33M | -$3.48M | $67,344 |
| EPS? | $-0.05 | $-0.81 | $-0.40 | $0.01 | $-1.27 | $-1.37 | $-1.03 | $-2.31 | $-0.43 | $0.01 |
| Diluted EPS? | $-0.05 | $-0.81 | $-0.40 | $0.01 | $-1.27 | $-1.37 | $-1.03 | $-2.31 | $-0.43 | $0.01 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality